ADJUVANTED FORMULATION OF SANOFI PASTEUR H5N1 PANDEMIC INFLUENZA VACCINE CANDIDATE DEMONSTRATES SIGNIFICANT IMMUNE RESPONSE

Lyon, France – May 11, 2006 – A study published online in The Lancet on May 11 demonstrated that multiple dosage formulations of a candidate H5N1 influenza vaccine developed by sanofi pasteur were well-tolerated and generated an immune response, with and without adjuvant. Of the formulations being tested, an alum-adjuvanted 30 microgram (µg) dosage generated the most substantive immune response (66.7% HI [haemaggluttination inhibition] seroconversion rate after two vaccinations) and was well-tolerated in the clinical study. Läs hela releasen i bifogat dokument.